Printsipy farmakoterapii obostreniy neoslozhnennogo khronicheskogo bronkhita, vyzvannykh bakterial'noy infektsiey -O.A. Mubarakshina 32 Obostrenie khronicheskoy obstruktivnoy bolezni legkikh. Rol' i mesto oral'nykh tsefalosporinov III pokoleniya


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review considers the current issues of treatment of chronic bronchitis in adults, and the principles of choice of antibacterial drugs depending on the severity of exacerbation and risk factors. Tactics of antibacterial treatment of exacerbations of uncomplicated chronic bronchitis is presented; the role of macrolide antibiotics in this pathology is discussed. The use of roxithromycin as one of the drugs of choice in the exacerbation of chronic lower respiratory tract infections is justified. The mechanisms of action of this drug, its pharmacological properties are presented; pharmacoeconomic rationale for the use of Esparoxy, generic roxithromycin, in the treatment of exacerbations of chronic bronchitis is discussed. Modern data on the tactics of mucolytic and expectorant therapy, and indications for its administration and principles of drug choice are demonstrated.

Full Text

Restricted Access

About the authors

O. A Mubarakshina

References

  1. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000:706-10.
  2. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. Смоленск, МАКМАХ, 2007. 464 с.
  3. Чучалин А.Г., Авдеев С.Н., Архипов В.В. и др. Рациональная фармакотерапия заболеваний органов дыхания. Руководство для практикующих врачей. М., 2004. 874 с.
  4. Pechere JC. New perspective on macrolide antibiotics. Intern J Antimicrob Agents 2001;18(1):92-8.
  5. Ноников В.Е. Антибактериальная терапия при инфекционно-зависимой бронхиальной астме// Consilium Medicum 2002. Т. 4. № 9.
  6. Синопальников А.И., Андреева И.В., Стецюк О.У. Безопасность макролидных антибиотиков: критический анализ // Клиническая медицина 2012. № 3. С. 23-30.
  7. Карпов О.И. Макролиды при обострении хронического обструктивного бронхита: есть ли перспективы?// Consilium Medicum 2005. Т. 7. № 4. С. 281-84
  8. Markham A, Faulds D. Roxithromycin: an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1994;48:297-326.
  9. Cooper BC, Mullins PR, Jones MR, et al. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae. A meta-analysis of 12 clinical studies. Drug Invest 1994;7:299-314.
  10. Portier H. Overview of the efficacy and safety of roxithromycin versus control antibiotics in the treatment of infections in adults. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu HC, Young LS, Zinner SH, Acar JF. (Eds.). New York, 1995:403-08.
  11. Karalus NC, Garrett JE, Lang S, et al. Roxithromycin 150 mg b.i.d. versus amoxicillin 500 mg/ clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice. Infection 1995;23:15-20.
  12. Bisetti A, Grassi L, Fiorucci F, et al. Open randomized comparison of activity and tolerance of roxithromycin vs clarithromycin in the treatment of lower respiratory tract infections. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 271.
  13. Young RA, Gonzalez JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989;37:8-41.
  14. Labro MT, El Benna J, Abdelghaffar H. Modulation of human polymorphonuclear neutrophil function by macrolides: preliminary data concerning dirithromycin. J Antimicrob Chemother 1993;31(Suppl. C):51-64.
  15. Scaglione F, Rossini G. Comparative antiinflammatory effect of roxithromycin, azithromycin and clarithromycin. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, 1996: abstr. 9.04.
  16. Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu HC, Young LS, Zinner SH, Acar JF. (Eds.). New York, 1995:51-60.
  17. Bryskier A, Butzler JP. Macrolides. In: Antibiotic and chemotherapy: anti-infective agents and their use in therapy. O'Grady E, Lambert HP, Finch RG, Greenwood D. (Eds.). Churcill Livingstone. New York, 1997:377-93.
  18. Pechere JC. Clinical evaluation of roxithromycin 300 mg once daily as an alternative to 150 mg twice daily. Diagn Microbiol Infect Dis 1992;15(4):111S-17S.
  19. Begue P, Kafetzis DA, Albin H, et al. Pharmacokinetics of roxithromycin in paediatrics. J Antimicrob Chemother 1987;20 (Suppl. B):101-06.
  20. Gialdroni Grassi G, Grassi C. Clinical application of macrolides and azalides in Legionella, Mycoplasma, and Chlamydia respiratory infections. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu HC, Young LS, Zinner SH, Acar JF. (Eds.). New York, 1995:95-119.
  21. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-131.
  22. Karalus NC, Garrett JE, Lang S, et al. A clinical and economic comparison of roxithromycin 150 mg twice daily vs. amoxicillin 500 mg/clavulanic acid 125 mg three times daily for the treatment of lower respiratory tract infections in general practice. Drug Invest 1994;8:179-90.
  23. Leeper KV, Jones АМ, Tillotson G. The changing bacterial etiology of chronic obstructive pulmonary disease (COPD). Chest 1997;112:21S.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies